Microbubble Contrast Ultrasound and Transient Elastography Imaging of Early Breast Cancer
Overview
- Phase
- N/A
- Intervention
- Perflutren lipid microsphere
- Conditions
- Ductal Carcinoma In-situ
- Sponsor
- Sunnybrook Health Sciences Centre
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Evidence of the presence of angiogenic tumour vasculature in patients diagnosed with DCIS utilizing contrast enhanced ultrasound.
- Status
- Terminated
- Last Updated
- 10 years ago
Overview
Brief Summary
This is a pilot study designed to investigate new techniques to guide the appropriate diagnosis and treatment of Ductal Carcinoma In-situ (DCIS). The microvascularity and stiffness of the lesion may be prognostic factors that can guide the need for more or less extensive therapy or perhaps only imaging follow-up may be needed.
Detailed Description
Women who have imaging findings suggestive of DCIS, who are having breast ultrasound and who are candidates for surgery will be eligible. They will receive a contrast-enhanced breast ultrasound after the intravenous injection of a microbubble contrast agent which will show the microvascularity. A subset of women will also have ultrasound elastography performed of the abnormality to evaluate its stiffness.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A woman with imaging signs suggesting a diagnosis of DCIS who is scheduled for ultrasound and a biopsy is eligible for the study.
- •At least 18 years of age
Exclusion Criteria
- •Pregnant or possibly pregnant or breast feeding
- •Unable to provide informed consent
- •Drug or multiple allergies
- •Known cardiac shunts
- •Known cardiac or chronic pulmonary disease
- •Hypersensitivity to perflutren
Arms & Interventions
Contrast perfusion and elastography arm
Intravenous injection of microbubble contrast agent and elastography
Intervention: Perflutren lipid microsphere
Outcomes
Primary Outcomes
Evidence of the presence of angiogenic tumour vasculature in patients diagnosed with DCIS utilizing contrast enhanced ultrasound.
Time Frame: The participant will be followed up till the results of the biopsy, an expected average of 3 months.
Secondary Outcomes
- Measurement of transient shear wave elastography .(The participant will be followed up till the results of the biopsy, an expected average of 3 months.)